Technical Analysis for PTGX - Protagonist Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 1.37% | |
| Upper Bollinger Band Walk | Strength | 1.37% | |
| Multiple of Ten Bullish | Other | 1.37% | |
| Above Upper BB | Strength | 1.37% | |
| Gapped Up | Strength | 1.37% | |
| Overbought Stochastic | Strength | 1.37% | |
| Up 3 Days in a Row | Strength | 1.37% | |
| Upper Bollinger Band Touch | Strength | 1.37% | |
| NR7 | Range Contraction | 7.74% | |
| Upper Bollinger Band Walk | Strength | 7.74% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 2 hours ago |
| Up 1% | about 3 hours ago |
| 60 Minute Opening Range Breakout | about 5 hours ago |
| Down 1% | about 6 hours ago |
| Fell Below Upper Bollinger Band | about 6 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Ulcer Abdominal Pain Colitis Crohn's Disease Chemical Entities Hepcidin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Ulcer Abdominal Pain Colitis Crohn's Disease Chemical Entities Hepcidin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 33.34 |
| 52 Week Low | 13.72 |
| Average Volume | 569,192 |
| 200-Day Moving Average | 22.28 |
| 50-Day Moving Average | 27.75 |
| 20-Day Moving Average | 26.68 |
| 10-Day Moving Average | 27.75 |
| Average True Range | 1.29 |
| RSI (14) | 73.96 |
| ADX | 19.75 |
| +DI | 39.74 |
| -DI | 12.42 |
| Chandelier Exit (Long, 3 ATRs) | 28.39 |
| Chandelier Exit (Short, 3 ATRs) | 28.08 |
| Upper Bollinger Bands | 30.20 |
| Lower Bollinger Band | 23.15 |
| Percent B (%b) | 1.18 |
| BandWidth | 26.42 |
| MACD Line | 0.65 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.6638 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 34.95 | ||||
| Resistance 3 (R3) | 34.82 | 33.54 | 34.37 | ||
| Resistance 2 (R2) | 33.54 | 32.65 | 33.60 | 34.18 | |
| Resistance 1 (R1) | 32.50 | 32.10 | 33.02 | 32.63 | 33.98 |
| Pivot Point | 31.22 | 31.22 | 31.48 | 31.28 | 31.22 |
| Support 1 (S1) | 30.18 | 30.33 | 30.70 | 30.31 | 28.96 |
| Support 2 (S2) | 28.90 | 29.78 | 28.96 | 28.76 | |
| Support 3 (S3) | 27.86 | 28.90 | 28.57 | ||
| Support 4 (S4) | 27.99 |
